Pathway link ERK-TSC

ERK / RSK (MAPK) ⊣ TSC1/TSC2

ERK / RSK (MAPK) inhibits TSC1/TSC2.

A separate growth pathway also disables the TSC brake – a third route into mTORC1 that drugs blocking only PI3K/Akt can't shut down.

ERK phosphorylates TSC2 and inactivates the TSC complex, so Ras-MAPK growth signalling converges on the same brake that Akt releases. This is the third upstream arm alongside PI3K/Akt and AMPK, and clinically it is a route to mTORC1 activation that PI3K inhibitors do not close.

The conditions it holds under

Single-study edge in this corpus; Roux 2004 describes the parallel RSK arm and is not yet held.

Time it takes

minutes

Step

direct (one molecule acts on the other)

Measured in

mammalian cells

Where in the cell

cytosol

Reaches people?

plausible in people, not shown directly

How settled

emerging, few independent studies

Studies behind it

Points the other way

No study in the Atlas contradicts this link. That means none in this curated set, not none in the literature.

Who has checked this

Checked by

No researcher outside the project has checked this link yet.

Curator sign-off

Not signed off yet. This link was drafted with AI help and has not been reviewed link by link; treat it as a proposal until it is.

Curated by

Oliver Barton, with AI help for drafting; see how links are checked.

“Inhibits” describes the effect on the target's activity, not on how much of it there is.

“How settled” describes how far researchers in the field agree. It is not the same as the sign-off above, which only says whether a named curator has checked this page.

If this link rests on your own work: a click on “This looks right” below, or a short note through “Report an error”, helps us more than anything else on this page.

← The whole pathway · This link as JSON